Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Polycythemia Vera 1Neoplasms 1Multi-centric Castleman's Disease 1Melanoma 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphadenopathy 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1HIV Infections 1

Interventions

Cyclophosphamide 29fludarabine phosphate 22Whole-Body Irradiation 20Mycophenolic Acid 20fludarabine 19asciminib 19nilotinib 16Tacrolimus 13Imatinib Mesylate 13Melphalan 11Dasatinib 9Sirolimus 8Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Granulocyte Colony-Stimulating Factor 7Busulfan 7bosutinib 6Mesna 6Cyclosporine 6ponatinib 5Stem Cell Transplantation 5Filgrastim 5venetoclax 4ruxolitinib 4blinatumomab 4Specimen Handling 4Cyclosporins 4thymoglobulin 3Bone Marrow Transplantation 3Antilymphocyte Serum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Interferon-alpha × 1 year × Clear all
NCT00015847 2025-08-22

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

OHSU Knight Cancer Institute

Phase 2 Terminated
25 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡